Monday, 16 June 2014

Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012 - 2018

Posted on 06:03 by Sandy Researcher

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Multiple Sclerosis Drugs Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. 

 Multiple sclerosis (MS) is an inflammation of fatty myelin sheaths around the axons of the brain and spinal cord. MS tends to affect the ability of nerve cells to communicate with each other in the brain and spinal cord. MS affects people with random symptoms based on the location and severity of attack. One event can last for days, weeks or months and can affect any part of the body. Symptoms include imbalance, loss of motor function, spasms, numbness, incontinence, and difficulty in swallowing. 

There is no known cure for the disease currently and the only drugs available in the market are for delaying the progression of the disease. MS is estimated to affect 2.5 million people worldwide with around 5000 new cases developing each year. The National Multiple Sclerosis Society, Multiple Sclerosis Foundation, Multiple Sclerosis Association of America and several others are organizations which are determined to ensure improvement in the lives of affected people to make them more educated and spread awareness of this disease.
 
Until the last year, the MS drugs market was led primarily by injectables, yet this trend is changing very quickly to give way to oral MS drugs which is expected to grow strongly beginning from 2013. Gilenya and Aubagio are the top current oral drugs in this segment and Biogen’s oral BG-12 and Teva Laquinimod are two other drugs in the pipeline for approval with a significantly higher efficacy to be launched in the next five years. Although oral MS drugs seem to be growing quickly, it is not expected that they would unsettle injectables anytime soon. Several fatal side effects have been linked to use of Gilenya among those who have a heart disease and thus shows that there is still a long way to go for oral MS drugs. Top contenders in this segment till now are Copaxone, Avonex, Rebif, Betaseron, and Tysabri. Most of these drugs work actively to control MS relapses. Other treatments such as stem-cell transplantation are currently under investigation. The process includes the injection of stem cells which will replace the affected inflamed and diseased cells, greatly improving patient’s quality of life.
 

About Us:
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information.

Contact Us:
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Browse Market Research Report:-
http://marketingfirmblog.wordpress.com/
http://marketsresearchreports.wordpress.com/.
Posted in , , , , | No comments

Global Pediatric Drugs Market - Industry Analysis, and Market Forecast, 2013 - 2019

Posted on 05:01 by Sandy Researcher

Transparency Market Research Reports included a detailed market survey and analysis trends on “Pediatric Drugs Market”. This report also includes more info about basic overview of the industry including definitions, applications and global market industry structure.

Pediatric drugs are a special class of drugs which are prescribed to children and infants for different diseases.  These drugs are recommended in various conditions such as asthma, anorexia, birth defects, cancer in children, growth deficiencies, juvenile diabetes, attention deficit hyperactivity disorder, and others. Various acts have been passed to control pediatric drugs such as Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). These acts have been introduced to increase the investments on R&D for pediatric drugs and to increase the drugs count prescribed for children and infants.

Browse Full Report with TOC :- 

Pediatric drugs are categorized in three segments namely pediatric clinical pharmacology, pediatric pharmacotherapy and pediatric pharmacy. Pediatric pharmacotherapy focuses on those drugs which will behave differently in children and adults. Pediatric clinical pharmacology includes those drugs which are helpful for mental and physical growth. Pediatric pharmacy includes all those drugs which are specifically meant for children. To treat various disease conditions different drugs are prescribed such as acetaminophen, fentanyl, ibuprofen, naloxone and methadone are given as analgesics. In addition, cefazolin, ampicillin and meropenem are prescribed to treat microbial infections whereas clonidine and etomidate are recommended for sedative effect. Various other drugs are tramadole, oxycodone, codeine, lorazepam and gabapentin.

Growing concerns globally, amongst parents has assisted the growth of this segment. Moreover, governments worldwide are funding and initiating various national programs to support use of drugs to curb infant and child mortality rates. Rise in disposable income along with awareness in people has augmented the growth of pediatric drugs in developed nations such as U.S. and Europe. In addition, rising incidence of disease conditions such as obesity, diabetes and hypertension in children have also contributed in its growth. Despite various developments, low disposable income and unawareness in developing nations are hindering the growth of this market. Moreover, side effects such as anxiety, headache and fatigue are also restricting its growth.


This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
Follow In LinkedIn :- 

This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Enquiry before Buying :- 

 About Us:-

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

Contact Us :-

Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Posted in , , | No comments

Protein Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

Posted on 03:18 by Sandy Researcher
Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Protein Drugs Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure.

The pharmaceutical industry is witnessing a shift in focus from molecular drugs to protein based drugs due to its high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity. The market for protein drugs is segmented into antibody drugs, peptide hormones, blood products and enzymes market. The antibody segment is one of the fastest growing areas in this market. Some of the commercially available antibody drugs are Adcetris (brentuximab vedotin) marketed by Seattle Genetics and Millennium/Takeda and Kadcyla (trastuzumab emtansine) marketed by Genentech and Roche. Insulin was the first peptide isolated and used as a therapeutic agent. Today there is a long list of peptides used therapeutically such as octreotide used in cancer treatment, amylin, pramlintide and glucagon-like peptide-1 (GLP-1). Rituxan (rituximab), Erbitux (cetuximab) are leading brand names in the monoclonal antibodies segment.


Continued development in the arena of proteomics and nanotechnology, improved protein based drug efficacy and safety, advances in drug delivery system and rapid increase in chronic diseases are some of the major factors supporting the growth of this market. Geographically, North America represents the largest market, as majority of the key players are domiciled in United States and thus many new drugs first are introduced in these regions. Other factors contributing growth in these regions are a large population base affected with chronic and autoimmune diseases and reimbursement policy covering almost major chronic diseases such as diabetes, cardiovascular and autoimmune diseases. North America is followed by Europe and Asia-Pacific. Emerging countries in Asia-Pacific and Latin America including India, China, Brazil and Mexico are predicted to experience a substantial growth due to improved economic scenario and continued improvement in healthcare facilities.

Some of the prominent players operating in this market space are Eli Lilly, Abbott Laboratories, UCB Group, Schering-Plough Corporation, Genentech Inc., Johnson & Johnson, Bristol-Myers Squibb, Novo Nordisk, Biogen Idec, Dendreon Corporation and Amgen Inc.

Browse More Research Report on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us:
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information.
Contact Us:
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Browse Market Research Report:-

Posted in , , , , | No comments

Research on Alzheimer's Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012 - 2018

Posted on 02:45 by Unknown
Alzheimer's Drugs Market
Alzheimer’s disease is a neurological disorder of the brain which is progressive and ultimately leads to loss of neurons. This condition leads to loss of memory and reasoning abilities. Currently, there is no treatment for Alzheimer’s, although there are certain ways of slowing down its progression. Physicians generally prescribe neurotransmitters like cholinesterase inhibitors, memantine, etc. to slow down the advancement of disease and improve some symptoms such as insomnia, depression, anxiety and agitation.


The global Alzheimer’s drugs market is expected to show a sluggish growth in coming years due to lack of significant facilities for disease diagnosis and treatment. North America held the majority of market share covering more than half of the market. However, this market has immense growth opportunities in the emerging economies of Asia-Pacific such as India, China, Russia and Australia due to prevalence of unmet medical needs. The increase in aging population serves as a major driver of Alzheimer’s drugs and treatment market. Unmet medical needs had led to the focus on the area of research and development which ultimately results in new product introduction and hence contributes to the market growth.

Early diagnosis of Alzheimer’s disease is not possible and there is a strong need of early detection techniques. Expiry of several patents could pose a serious threat in the growth of this market. Some of the major players in the Alzheimer’s drugs market include companies such as Forest Laboratories, Inc., Eisai Co., Ltd., H. Lundbeck A/S., Novartis AG, Pfizer Incorporation and others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
·         North America 
·         Asia Pacific 
·         Europe
·         Rest of the World  

This report provides comprehensive analysis of 
·         Market growth drivers 
·         Factors limiting market growth
·         Current market trends 
·         Market structure
·         Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.




Contact Us

Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.

Tel: +1-518-618-1030

Browse Market Research Blogs:
Posted in , , , | No comments

Thursday, 12 June 2014

Geriatric Medicine Market - Industry Research Report and Forecast, 2013 – 2019

Posted on 01:25 by Sandy Researcher
Geriatric is the branch of medicine concerned with clinical, remedial, preventive and social aspects of illness usually among people over 65 years of age. In response to the needs and demands of an aging population, demand for geriatric medicines has grown rapidly in last 3 decades. The elderly patients across the globe face an array of ill health conditions which include co-morbid complexities such as falls, cerebral ageing and syncope among others. According to Eurostat the number of people aged 65 tears and above is likely to be 141 million by 2050 which is approximately 17%-30% increase in specific population group as compared to 2008 geriatric population. An article published by the Indian Express in June 2014 stated that people aged 60 years and above are likely to reach 323 million mark by 2050.

Browse Full Report with TOC:


In present scenario the approximately 80% of India’s elderly population lives in rural area of which 40% of them lives below poverty line. Such conditions significantly increase the risk for adverse drug reaction events especially among geriatric population as one third of the emergency admissions in elderly people is due to drug related In 2010 approximately 45-50% of the prescriptions were written for people aged 60 and above and one in three patients took at least 5 drugs or more on a daily basis in United States.

In last three decades, geriatric medicines have experienced substantial growth due to which it has now become a prominent part of the American medicines. Notable accomplishment in growth include establishment of National Institute on Aging whose mission is to improve health and well-being of older Americans through research and identification of new clinical interventions. In general geriatric medicines market can be segmented in two prominent sub classes namely drug therapy and geriatric services.

More Reports On Pharmaceutical Market :


The drug therapy include treatment and care with respect to prominent geriatric diseases such as diabetes, skin diseases due to extrinsic conditions, congestive heart failure diseases, atherosclerosis, memory impairment, dementia, urinary disorders and others. Probiotics are another emerging area of opportunities in forthcoming years for geriatric care. Whereas, the geriatric services market include advance care planning, home care services, nutritional care, socialization programs, education and awareness and sleep management are among the prominent areas of opportunities for new and existing players.

Major drivers that will positively uplift and boost the demand and growth for geriatric medicines market include increasing trend with respect to electric record among physicians which reduces the patient discomfort and helps practitioners having continuous patient monitoring. Apart from this innovations related to multiple chronic disease treatment, increasing collaboration of lay organization and NGOs with professional group will drive the geriatric market in coming years. Some of the major restraints to this market include lack of patient participation in clinical trials leading to development of vaccines or drugs that are not completely studied and safe.

Enquiry before Buying :-http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2445

This leads to lot of health issues and adverse effects in past one decade. Lack of specialized care centers and hospital units are another major factor responsible for low geriatric patient care. Only 40% - 45% of the US geriatric population avail the proper treatment despite of technological advancements and infrastructure reforms.
Some of the prominent players in geriatric medicines market include Geri-Care pharmaceuticals, Nausicaa Medical, Geriatric & Medical Companies, Inc., Nutricap Labs, UAS Laboratories and others.

Follow In LinkedIn:- https://www.linkedin.com/today/post/article/20140612053905-271457835-geriatric-medicine-market-2013-2019

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

·         North America
·         Asia Pacific
·         Europe
·         Rest of the World

This report provides comprehensive analysis of

·         Market growth drivers
·         Factors limiting market growth
·         Current market trends
·         Market structure
·         Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:-
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

Contact Us :-
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Browse Market Research Report:-
http://researchreportsindustry.wordpress.com/

http://marketingfirmblog.wordpress.com/
Posted in , , | No comments

Wednesday, 11 June 2014

Global Epilepsy Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

Posted on 23:30 by Sandy Researcher
Transparency Market Research Reports included a detailed market survey and analysis trends on “Epilepsy Therapeutics Market”. This report also includes more info about basic overview of the industry including definitions, applications and global market industry structure.

Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends wrong signals. Seizures could differ from primary generalized seizures to partial seizures depending upon the cause of the epilepsy.  Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. For the treatment of epilepsy, doctors prescribe antiepileptic medicines (AEDs) and the preference for the drug depends on the type of seizures to be treated, age of the patient, part of the brain involved and seriousness of the seizures.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html

On the basis of the available AEDs, epilepsy therapeutics market is segmented into two major categories namely first generation AEDs and second generation AEDs. First generation AEDs consist of following drugs:
  • Carbamazepine (Carbatrol)
  • Valproate (Depakote)
  • Oxycarbazepine ((Trileptal)
  • Phenytoin (Dilantin, Phenytek) 
  • Ethosuximide (Zarontin)
  • Phenobarbital (Luminal)
  • Primidone (Mysoline)
  • Topiramate (Topamax)
Second generation AEDs consist of medicines with different mechanism of action than the first generation drugs. This segment of epilepsy therapeutics market consists of following drugs:
  • Pregabalin (Lyrica) 
  • Lamotrigine (Lamictal) 
  • Levetiracetam (Keppra) 
  • Zonisamide (Zonegran) 
  • Lacosamide (Vimpat) 
  • Eslicarbazepine acetate (Aptiom/Zebinix) 
  • Perampanel (Fycompa) 
  • Ezogabine/retigabine (Trobalt/Potiga) 
  • Rufinamide (Banzel/Inovelon)
First generation AEDs majorly carbamazepine, valproate, phenytoin and oxycarbazepine dominates the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the epilepsy therapeutics market due to its improved efficacy and tolerability. Additionally, large number of research and development activities, are going on all over the world for the development of antiepileptic medicines with diverse mechanism actions. As for instance two major players of epilepsy therapeutics market namely UCB Pharma Ltd. and Marinus Pharmaceuticals, Inc. has developed brivaracetam and ganaxolone respectively, for treating epilepsy. Both of these drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.
North America leads the epilepsy therapeutics market followed by Europe majorly due to the extensive research and development activities and availability of second generation drugs. Three new AEDs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate and it expected that brivaracetam will be approved soon. 

Ezogabine/retigabine and perampanel among these have novel mechanism of action and thus it is capturing good amount of market share in U.S. Continuous increase in uptake of second generation AEDs is also driving the epilepsy therapeutics market in North America and Europe. Asia-Pacific is also increasing at faster pace for epilepsy therapeutics market. High prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is restraining the epilepsy therapeutics market in this region. 
Some of the major players in epilepsy therapeutics market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.

More Report on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
·         It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Download PDF: Global Epilepsy Therapeutics Market

About Us:
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information.

Contact Us:
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Browse Market Research Report:-
http://marketingfirmblog.wordpress.com/

http://marketsresearchreports.wordpress.com/.
Posted in , , , , | No comments

Monday, 9 June 2014

Blood Glucose Test Strips Market – Industry Research Report and Forecast, 2013 - 2019

Posted on 04:15 by Sandy Researcher
Blood glucose or blood sugar refers to the sugar passed through the blood stream that is responsible for ensuring the energy supply to all the cells in the body. The regulation of blood glucose levels is essential in order to maintain the normal levels thereby maintaining hemostasis (maintaining a stable or equilibrium condition in the blood’s internal environment). The state of hemostasis is necessary for our bodies to ensure proper functionality.

Browse Full Report with TOC : 

There exist different types of blood glucose measurement tests performed such as fasting blood sugar test, postprandial blood sugar, oral glucose tolerance test, glycohemoglobin A1c testing and random blood sugar testing. Deviation in blood glucose levels from the normal range results in the development of disorders such as hyperglycemia and hypoglycemia. Hyperglycemia refers to a condition characterized by high levels of blood sugar than normal range whereas hypoglycemia refers to a condition characterized by lower blood glucose levels than normal range. Research studies have proved that higher levels of blood glucose levels lead to increased risk of developing cardiovascular diseases both in diabetic and non-diabetic population.

Blood glucose monitoring is referred to the regular testing of glycemia (testing the levels of glucose). Usually the blood glucose levels are monitored by either using a glucose meter comprising lancets, test strips and logbooks. In January 2014, the U.S. Food and Drug Administration (FDA) proposed the new draft guidance for blood glucose test strips. The FDA has issued for the first time two separate guidance drafts for blood glucose test strips of which one is focused on point of care prescription meters (used in hospitals) and the other for over-the-counter (OTC) products.

More Reports On Pharmaceutical Market : 

The scope for allowable range of errors has been tightened from plus or minus 20% to plus or minus 15%. Similarly, the range of errors in case of point of care meters is also tightened. The other requirements would be the disinfection requirements and the packaged maters would contain the information about the accuracy results of the products. This would help the buyers to select the appropriate test strips. Another major requirement that FDA had added is that it would review the manufacturers test strips release lot that means there would be more stringent scrutiny for the clearance of test strips. Hence, these guidelines would ensure safety along with high reliability and accuracy and also reduce the probability of product recalls by the respective companies.

The market for blood glucose test strips can be segmented based on the test strips available for hospital use and over the counter products. Also, a detailed geographical landscape elucidating the market trends for four major geographies can be provided. The major factors favoring the growth of the blood glucose test strips market is consistent increase in the prevalence of diabetes along with increasing obesity and increased physical inactivity. As per the data enumerated by the International Diabetes Federation, in the year 2013 there are around 382 million people suffering from diabetes worldwide of which 37 million are Americans, 72 million people in South East Asian countries and around 56 million in European countries and others. In addition, rise in technological advances and increased awareness about diabetes is leading to increased diagnosis rates both at hospitals and at individual level.

These factors would in turn enhance the adoption of blood glucose test strips and drive the market growth. On the other hand, lack of accuracy, reliability, and increasing product recalls by several manufacturers would impede the market growth. Some of the key market players competing in this market are Abbott Laboratories, Bayer Healthcare AG, LifeScan, Inc., and F.Hoffmann-La Roche Ltd.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.


About Us:-
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

Contact Us :-
Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Browse Market Research Report :-
http://researchreportsindustry.wordpress.com/
Posted in , | No comments
Subscribe to: Posts (Atom)